• Nyrada raises $8.25 million in new equity capital from institutional, professional and sophisticated investors
• Funds will be used to conduct Phase IIa clinical trial of Xolatryp, develop non-infusion formulation, and further research
• Placement follows recent announcement of planned Phase IIa trial to assess safety and efficacy of Xolatryp in acute myocardial infarction

Nyrada Inc. (ASX:NYR), a clinical stage drug discovery and development company, has successfully raised $8.25 million in new equity capital through a placement to new and existing institutional, professional and sophisticated investors. The placement issue price was $0.30 per CDI, representing an 18.9% discount to the last traded price and a 5.0% discount to the 15-day volume weighted average price. The funds raised will be used to conduct a Phase IIa clinical trial to assess the safety and efficacy of Nyrada's lead candidate Xolatryp in patients with acute myocardial infarction, develop a non-infusion formulation of Xolatryp, undertake GMP manufacture of Xolatryp, and further research the compound in other potential indications. The placement follows Nyrada's recent announcement of its planned Phase IIa trial for Xolatryp, which is nearing completion of its first-in-human Phase I clinical trial. Nyrada's CEO and Chair commented on the strong investor support and the exciting and pivotal period ahead as the company advances Xolatryp towards the critical Phase IIa milestone. The placement is being issued in two tranches, with the first tranche of 26.5 million CDIs expected to settle on 8 August 2025 and the second tranche of 1 million CDIs on 19 August 2025. Additionally, Nyrada's directors and management have agreed to subscribe for $0.1 million worth of CDIs on the same terms as the placement, subject to shareholder approval at the company's AGM in November 2025.

Nyrada expects the new capital, along with anticipated R&D tax rebates and options exercise proceeds, to provide sufficient funding to complete the Phase IIa clinical trial of Xolatryp, develop a non-infusion formulation, undertake GMP manufacture, and further research the compound in other potential indications.

Nyrada is now fully funded to complete a Phase IIa clinical trial in cardioprotection, drug manufacture and formulation, and low-cost studies into other indications. The company is focused on delivering economic and therapeutic value as it continues to progress Xolatryp towards this critical milestone.